Moderna, Carisma collaborate to develop CAR M for oncology

By The Science Advisory Board staff writers

January 11, 2022 -- Moderna and Carisma Therapeutics have entered into a strategic collaboration agreement to discover, develop, and commercialize in vivo engineered CAR macrophage (CAR M) therapeutics for the treatment of cancer.

Under the agreement, Carisma will receive a $45 million upfront cash payment and an investment by Moderna in the form of a $35 million convertible note. Carisma will receive research funding and is eligible to receive development, regulatory, and commercial milestone payments plus royalties on net sales of any products that are commercialized under the agreement.

Carisma will be responsible for the discovery and optimization of development candidates while Moderna will lead the clinical development and commercialization of therapeutics resulting from the agreement. Moderna has the option to nominate up to 12 targets for development and commercialization.

Moderna has transformed from a research-stage company advancing programs in the field of mRNA to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities.

Carisma is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response.

Moderna launches AI academy with Carnegie Mellon University
Moderna has launched the Artificial Intelligence (AI) Academy for its employees in partnership with Carnegie Mellon University. The AI Academy is intended...
FDA expands EUA for Pfizer, Moderna COVID-19 vaccine boosters
The U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for booster shots of both the Pfizer-BioNTech COVID-19...
FDA authorizes COVID-19 vaccine booster shots
Johnson & Johnson and Moderna have received emergency use authorization from the U.S. Food and Drug Administration (FDA) for booster shots of their...
Carisma to develop allogeneic macrophage therapies
Carisma Therapeutics has established a multiyear scientific collaboration with Dr. Bruce Blazar of the University of Minnesota to investigate and...
Carisma, NYU Langone to develop Vpx lentiviral vector
Carisma Therapeutics has entered into a scientific research and licensing agreement with NYU Langone Health to attain exclusive rights to develop and...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter